Page 6 - Flipbook
P. 6
Bladder cancer management by stage
NMIBC MIBC METASTATIC
Low
Grade High Grade Cystectomy Bladder Cisplatin Cisplatin Platinum-ineligible
candidate Preservation Eligible Ineligible
Clinical trials
TURBT+/- BCG
IO+BCG
Gem-Cis Gem-Carbo Pembrolizumab or
atezolizumab
Tri-
Cis-eligible Cis-ineligible modality
BCG NAC (cystectomy) Therapy
Refractory
Clinical trials Clinical trials Clinical PD SD, PR or CR
IO+/-NAC IO+/-NAC trials
IO+/-EV Avelumab
pembrolizumab
Radical Pembrolizumab maintenance
Cystectomy (CIS+) Radical
Cystectomy
Clinical trials PD
Enfortumab Vedotin
Adjuvant Sacituzumab govotecan
Chemotherapy Nivolumab Erdafitinib
if cis-eligible
and no NAC
